Vice President, Clinical Development
Reggie Ewesuedo
As Vice President of Clinical Development, Reggie is responsible for the direction, and execution of Lantern’s clinical development plans, and involved in the strategy of the development of the portfolio of programs.
Prior to joining Lantern in 2023, Reggie had spent over 20 years involved in extensive preclinical, early phase and late phase drug development research activities including as a clinical research Faculty at The Ohio State University, and at Astrazeneca, Genzyme, Sanofi, Pfizer, Tesaro/Glaxo Smith Kline and Kymera. Reggie served as a senior medical director and global medical lead for development of several drugs while at Pfizer that led to successful filings for TrazimeraTM (trastuzumab-qyyp), NyvepriaTM (pegfilgrastim-apgf) and ZirabevTM (bevacizumab-bvzr). In addition, Reggie also held various leadership roles in Experimental Medicine in Astrazeneca, and in clinical development in Genzyme, Tesaro/GSK and Kymera during which time he led various aspects of both the medical and clinical pharmacology evaluation of several oncology and non-oncology drugs that informed the use of approved drugs such as Cediranib (AZD2171, RecentinTM), Clolar® (clofarabine), Mozobil (plerixafor), Zejula (niraparib) and Jemperli (dostarlimab-gxly).
Reggie received his MBBS degree (MD equivalent) from University of Ibadan, Nigeria, M.Sc. in Clinical Pharmacology from Ahmadu Bello University, Nigeria, and MBA from Greehey School of Business at St. Mary’s University. He has authored more than 20 peer-reviewed papers published in top-tier medical and scientific journals and chapters in Oncology textbooks. He trained in the subspecialties of Hematology & Pediatric Oncology, and Clinical Pharmacology & Pharmacogenomics at the University of Chicago. He is Board certified in Pediatric Hematology/Oncology and Clinical Pharmacology.
